May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Ovarian Cancer
Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
Trametinib Slows Recurrent Low-Grade Serous Ovarian Carcinoma
Median progression-free survival significantly prolonged with trametinib versus one of five standard-of-care treatment options
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Cytalux Approved to Detect Ovarian Cancer Lesions During Surgery
Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions.
Nemvaleukin Alfa Plus Pembrolizumab Fast Tracked for Platinum-Resistant Ovarian Cancer
The antitumor activity and safety of nemvaleukin alfa plus pembrolizumab is being investigated in the open-label, randomized, phase 3 ARTISTRY-7 trial.
Oral Contraceptives Lower Ovarian Cancer Risk in BRCA Carriers
Findings seen in BRCA1 and BRCA2 mutation carriers; reduction greater with longer duration of use in BRCA1 carriers
Presence of Particulate Prompts Recall of Topotecan Injection
To date, Teva has not received any further complaints or adverse events reports related to this recall.
Carboplatin Alone Not Adequate for Ovarian Cancer in Frail Seniors
Worse survival than with combination carboplatin-paclitaxel regimens for vulnerable older patients with ovarian cancer
Pafolacianine Sodium Gets Priority Review for Ovarian Cancer Detection During Surgery
Pafolacianine sodium binds to folate receptors commonly found on many cancers, including ovarian and lung cancers, and illuminates the cancerous lesions under near-infrared light.
